A detailed history of Loomis Sayles & CO L P transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Loomis Sayles & CO L P holds 1,025,243 shares of CRSP stock, worth $57.4 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,025,243
Previous 1,067,351 3.95%
Holding current value
$57.4 Million
Previous $66.8 Million 4.59%
% of portfolio
0.1%
Previous 0.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$60.67 - $89.12 $2.55 Million - $3.75 Million
-42,108 Reduced 3.95%
1,025,243 $69.9 Million
Q4 2023

Feb 13, 2024

SELL
$38.62 - $72.18 $1.12 Million - $2.09 Million
-29,003 Reduced 2.65%
1,067,351 $66.8 Million
Q3 2023

Nov 09, 2023

SELL
$45.39 - $59.0 $2.34 Million - $3.04 Million
-51,575 Reduced 4.49%
1,096,354 $49.8 Million
Q2 2023

Aug 11, 2023

SELL
$43.47 - $67.77 $386,057 - $601,865
-8,881 Reduced 0.77%
1,147,929 $64.4 Million
Q1 2023

May 11, 2023

SELL
$41.0 - $56.12 $1.29 Million - $1.77 Million
-31,511 Reduced 2.65%
1,156,810 $52.3 Million
Q4 2022

Feb 10, 2023

SELL
$39.19 - $65.67 $2.23 Million - $3.74 Million
-56,878 Reduced 4.57%
1,188,321 $48.3 Million
Q3 2022

Nov 14, 2022

SELL
$61.1 - $83.78 $9.23 Million - $12.7 Million
-151,059 Reduced 10.82%
1,245,199 $81.4 Million
Q2 2022

Aug 05, 2022

BUY
$43.23 - $73.83 $4.55 Million - $7.78 Million
105,353 Added 8.16%
1,396,258 $84.9 Million
Q1 2022

May 13, 2022

SELL
$53.19 - $79.24 $1.34 Million - $2 Million
-25,218 Reduced 1.92%
1,290,905 $81 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $27.3 Million - $43.4 Million
390,209 Added 42.14%
1,316,123 $99.7 Million
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $1.9 Million - $2.7 Million
17,262 Added 1.9%
925,914 $104 Million
Q2 2021

Aug 13, 2021

BUY
$100.84 - $161.89 $91.6 Million - $147 Million
908,652 New
908,652 $147 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.36B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.